FDA grants Priority Review to Takeda’s zasocitinib after Phase 3 psoriasis studies, including head-to-head superiority versus deucravacitinib.
AbbVie has secured a broad pediatric label for Skyrizi, adding both plaque psoriasis and active psoriatic arthritis alongside a new dose for children weighing less than 40 kg. The approval could strengthen treatment choice, although the evidence supporting the two indications is not equally direct.
Find out how Akeso’s gumokimab approval could reshape China’s psoriasis biologics market and IL-17 competition.
Japan needs lower biologic costs. Samsung Bioepis’s NIPRO launch tests whether ustekinumab biosimilars can shift autoimmune care.
Psoriasis biologics are getting longer acting. Halozyme and Oruka now face the harder test of making high-dose therapy practical.
LEO Pharma has won China approval for Enstilar in plaque psoriasis. Read what it means for competition, access, and dermatology growth.
Takeda’s zasocitinib posted strong Phase 3 psoriasis data. Read what it changes for TYK2 competition, regulation, and oral treatment strategy.
Takeda Pharmaceutical Company Limited has reported positive topline results from two pivotal Phase 3 studies of its investigational drug zasocitinib (TAK-279), a once-daily oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis. The trials met all primary and secondary endpoints, with more than 50 percent of participants achieving near-complete skin clearance (PASI